相关实验视频

Updated: Jul 2, 2025

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

制备和评估含有曼吉费林的固体脂质纳米颗粒的抗糖尿病活性

Ahmed I Foudah¹, Mohammad Ayman Salkini¹, Mohammed H Alqarni¹

¹Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia.

Saudi journal of biological sciences

|February 22, 2024

概括

这项研究开发了含有曼吉费林的固体脂质纳米颗粒 (MG-SLNs) 用于糖尿病治疗. 在老鼠中,MG-SLNs有效降低了血糖,改善了脂质配置文件,并保护了肝酶.

科学领域:

纳米技术纳米技术
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

糖尿病是一种全球性健康问题,需要有效的治疗策略.
曼吉费林 (MG) 具有潜在的抗糖尿病特性,但面临生物可用性挑战.
固体脂质纳米颗粒 (SLN) 提供了一个有前途的药物输送系统,以提高治疗疗效.

研究的目的:

开发和优化含有曼吉费林的固体脂质纳米颗粒 (MG-SLNs) 以提高口服输送.
评估MG-SLNs的抗糖尿病活性和药理动力学特征.
在糖尿病老鼠模型中研究MG-SLNs在改善脂质代谢和肝功能方面的潜力.

主要方法:

使用微乳液技术和超声波与Labrafil M 2130 CS,Tween 80和乙醇进行配制MG-SLN.
物理化学表征包括粒子大小,多分散度指数,捕获效率和泽塔潜力.
在体外释放药物,共聚焦显微镜,分子对接,酶抑制试验 (α-氨酶,α-葡萄糖酶) 和在糖尿病大鼠体内实验进行了研究.

主要成果:

优化的MG-SLN显示了有利的特征:粒子大小 (138.37 nm),PDI (0.247),捕获效率 (84.37%) 和泽塔电位 (18.87 mV).
与自由曼吉费林相比,MG-SLNs的药物释放量增加了两倍,组织透率更深.
在体内研究显示,MG-SLNs显著且持续地降低了血糖水平,改善了脂质配置文件和肝脏保护作用.

结论:

开发的MG-SLNs代表了mangiferin的有效口服输送系统.
MG-SLNs具有显著的抗糖尿病潜力,改善血糖控制,脂质代谢和肝功能.
这种新的配方充满了希望,作为一种有效的治疗策略,用于管理糖尿病.

关键词:

糖尿病糖尿病糖尿病曼吉费林是一种基胺.纳米颗粒纳米颗粒预防机制的预防机制.

更多相关视频

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes

Published on: July 30, 2020

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...